Last updated: November 9, 2026

Iobenguane I-123 is a niche diagnostic radiopharmaceutical used primarily for imaging suspected or known pheochromocytoma and neuroblastoma. In the United States, the product is marketed as AdreView under NDA 022164. Its commercial profile is defined by low treatment volume, short radioactive half-life, specialized distribution, and competition from PET-based imaging rather than from conventional generic drugs. Product-level revenue is not publicly reported, so financial analysis relies on market structure, utilization drivers, supply economics, and disclosed corporate information rather than audited sales figures.

What is iobenguane I-123 and how is it used?

Iobenguane I-123 is an iodine-123-labeled norepinephrine analogue. It localizes in adrenergic tissue and is used with single-photon emission computed tomography or planar scintigraphy.

The FDA-approved indication covers diagnostic imaging in adults and pediatric patients 12 years and older with suspected or known pheochromocytoma or neuroblastoma. The product is not a therapeutic radiopharmaceutical. Its therapeutic counterpart, iobenguane I-131, is marketed separately as Azedra for the treatment of certain malignant or unresectable pheochromocytoma and paraganglioma cases. The two products have different isotopes, indications, safety profiles, and commercial economics.[1][2]

Attribute	Iobenguane I-123	Iobenguane I-131
Primary product	AdreView	Azedra
Function	Diagnostic imaging	Radiopharmaceutical therapy
FDA approval	2008	2018
Main disease use	Pheochromocytoma and neuroblastoma imaging	Malignant or unresectable pheochromocytoma or paraganglioma
Radiation profile	Diagnostic gamma emission	Therapeutic beta and gamma emission
Typical commercial model	Per-dose imaging supply	Treatment-course administration
Biosimilar pathway	Not applicable	Not applicable

Iodine-123 has a physical half-life of approximately 13.2 hours. That short half-life limits inventory, favors just-in-time manufacturing, and makes delivery radius a central commercial variable.[1]

What is the FDA regulatory status of AdreView?

AdreView was approved by the FDA in July 2008 under NDA 022164 for diagnostic imaging of suspected or known pheochromocytoma and neuroblastoma.[3] The product is a radiopharmaceutical drug, not a biologic, and therefore is not subject to the biosimilar framework under section 351 of the Public Health Service Act.

The label requires attention to radiation exposure, hypersensitivity, thyroid blockade, renal function, and pregnancy-related risks. Product administration also requires nuclear medicine infrastructure and trained personnel.[1]

FDA status and regulatory barriers

Regulatory item	Status
Active ingredient	Iobenguane I-123
Dosage form	Intravenous injection
FDA pathway	NDA
Reference product	AdreView
Primary indication	Diagnostic imaging
Biosimilar pathway	Not applicable
Administration setting	Nuclear medicine department or qualified imaging center
Main regulatory barrier	Manufacturing, isotope supply, quality control, and distribution reliability

The FDA approval created an established regulatory reference product, but it did not convert iobenguane I-123 into a mass-market pharmaceutical. Utilization remains concentrated in specialist hospitals and imaging centers.

How large is the iobenguane I-123 market?

The market is small relative to oncology therapeutics, radiology contrast agents, and established PET tracers. Public companies generally do not report AdreView sales separately. Revenue is typically embedded within broader diagnostic pharmaceutical, contrast media, or nuclear medicine segments.

Market size is constrained by four factors:

The addressable patient population is limited.
Imaging is concentrated in tertiary hospitals.
Many institutions have shifted toward PET-based alternatives where clinically appropriate.
The isotope’s short half-life raises logistics costs and limits geographic reach.

Demand is strongest in centers managing neuroendocrine tumors, hereditary pheochromocytoma and paraganglioma syndromes, pediatric neuroblastoma, and complex metastatic disease.

The economic unit is the administered dose rather than a recurring prescription. That makes revenue dependent on scan volume, referral patterns, isotope availability, reimbursement, and cancellation rates. A supply interruption can eliminate revenue for a scheduled dose because the product cannot be held for long periods without decay.

What drives the financial trajectory for iobenguane I-123?

The financial trajectory is more likely to be stable-to-declining in mature markets than rapidly expanding. Growth opportunities exist in specialized oncology imaging, but the product faces substitution from PET technologies and institutional pressure to standardize imaging pathways.

Demand drivers

Driver	Financial effect
Higher incidence of diagnosed neuroendocrine tumors	Supports imaging volume
Greater genetic testing for pheochromocytoma and paraganglioma	Expands surveillance demand
Growth in specialized cancer centers	Supports concentrated utilization
Improved referral to tertiary hospitals	Increases dose demand
Expanded pediatric oncology imaging	Creates targeted demand

Demand constraints

Constraint	Financial effect
PET adoption	Reduces use of SPECT-based imaging in some protocols
Short isotope half-life	Increases wastage and distribution costs
Limited nuclear medicine capacity	Caps the number of administering sites
Reimbursement variability	Pressures dose economics
Alternative imaging agents	Reduces dependence on I-123 MIBG
Low patient volume per site	Weakens local stocking economics

The product’s commercial durability comes from clinical familiarity and use cases in which MIBG imaging remains relevant. Its principal risk is not a traditional generic price collapse. It is gradual replacement by alternative imaging modalities, particularly PET agents with improved resolution or more favorable diagnostic performance in selected settings.

What patents protect iobenguane I-123 and AdreView?

The relevant intellectual-property analysis separates compound patents, isotope-labeling technology, formulation claims, manufacturing processes, and regulatory exclusivity.

A product-name review does not establish a single current patent-expiration date. The FDA Orange Book is the controlling public source for listed patents and regulatory exclusivity associated with an approved NDA.[4]

Patent and exclusivity position

IP category	Commercial assessment
Basic iobenguane chemistry	Likely mature and difficult to protect through new composition claims
Iodine-123 labeling	Potential process protection, but value depends on enforceability and design-around options
Injectable formulation	Possible narrow protection; limited commercial leverage if unlisted or expired
Manufacturing process	Can create operational barriers even without strong patent exclusivity
Clinical method of use	Narrower relevance because diagnostic use is established
FDA exclusivity	Original NDA exclusivity has expired
Biosimilar exclusivity	Not applicable
Orange Book significance	Relevant only to patents listed against the NDA

The commercial moat is therefore more operational than patent-driven. Production quality, isotope sourcing, validated release testing, shipping reliability, and hospital relationships can matter more than blocking patents.

When does iobenguane I-123 lose exclusivity?

The original FDA approval dates to 2008, so any standard five-year new chemical entity exclusivity has expired. Any three-year exclusivity associated with supplemental clinical data would also have expired by now unless tied to a later qualifying approval. Pediatric exclusivity, if granted, would add six months but would not materially change the current market position.[3][4]

The practical loss of exclusivity occurred years ago. The remaining commercial protection is based on manufacturing capability, regulatory compliance, customer access, and supply reliability.

A precise patent expiration date should not be inferred from the FDA approval date. Patent terms depend on filing dates, patent-term adjustment, patent-term extension, terminal disclaimers, and whether a patent was listed against the NDA.

How many patents cover AdreView?

No commercially material patent portfolio can be established from the product name alone without a current Orange Book and patent-family review. The relevant question is not the number of patents but whether an unexpired, listed patent would block an FDA-approved competing product.

For iobenguane I-123, the likely barriers are:

validated synthesis and radiolabeling methods;
sterile injectable manufacturing;
quality specifications for radionuclidic purity;
isotope procurement;
short-half-life distribution;
regulatory approval of a competing product.

A competitor may avoid patent exposure by using a different labeling process or manufacturing route. The more significant hurdle is proving consistent product quality before radioactive decay reduces usable shelf life.

Are there Paragraph IV challenges to iobenguane I-123?

No widely reported Paragraph IV dispute has materially reshaped the U.S. iobenguane I-123 market. Paragraph IV litigation is less commercially attractive for a small radiopharmaceutical than for a high-volume oral drug because the addressable market is narrow, manufacturing is specialized, and the potential damages base is limited.

A prospective ANDA or 505(b)(2) applicant would still need to evaluate:

any currently listed AdreView patents;
formulation and process patents;
FDA requirements for radioactive drug manufacturing;
comparative product characterization;
sterility and endotoxin controls;
isotope sourcing;
distribution validation.

The absence of prominent Paragraph IV litigation does not mean that competition is impossible. It indicates that the market has not generated the conventional generic litigation economics associated with blockbuster medicines.

What formulation and manufacturing barriers affect competition?

Iobenguane I-123 is supplied as a sterile injectable radiopharmaceutical. The product’s short half-life creates manufacturing and logistics risks that do not apply to ordinary injectable drugs to the same degree.

Key manufacturing barriers

Iodine-123 must be available on a reliable schedule.
Radiolabeling must meet validated purity and identity specifications.
Sterile production requires qualified facilities and aseptic controls.
Release testing must occur within a narrow time window.
Shipping routes must account for radioactive decay.
Inventory planning must match scheduled imaging volume.

These requirements favor established radiopharmaceutical manufacturers and regional distribution networks. A new entrant could obtain regulatory approval yet still struggle to achieve positive margins if it cannot aggregate sufficient dose volume or maintain high on-time delivery.

The manufacturing moat is strongest in markets with long shipping distances, limited cyclotron or isotope access, and low-density hospital demand.

How does iobenguane I-123 compare with PET-based imaging?

PET alternatives are the principal strategic threat. Gallium-68 DOTATATE and related somatostatin-receptor PET agents are used extensively in neuroendocrine tumor imaging, while fluorine-18-based tracers are relevant in selected oncology settings. These products may offer higher resolution, faster imaging, or broader adoption in institutions with established PET infrastructure.

Factor	Iobenguane I-123	PET alternatives
Imaging platform	SPECT or planar imaging	PET/CT
Isotope logistics	Short half-life and specialized delivery	Also time-sensitive, but often supported by larger PET networks
Main clinical niche	Adrenergic tumors, MIBG-avid disease, neuroblastoma	Neuroendocrine and other tumor-specific imaging
Infrastructure	Gamma camera and nuclear medicine capability	PET/CT and PET radiopharmacy
Competitive advantage	Established MIBG biology and clinical familiarity	Resolution, workflow, and expanding tracer availability
Commercial risk	Replacement in selected indications	Reimbursement and isotope availability

Iobenguane I-123 remains relevant where MIBG avidity is clinically important or where institutional protocols and physician expertise support its use. PET substitution is strongest when a competing tracer provides superior lesion detection or more actionable staging.

What is the commercial impact of Azedra on iobenguane I-123?

Azedra is not a direct substitute for AdreView, but the products share the MIBG platform and clinical ecosystem. AdreView is diagnostic; Azedra is therapeutic. Diagnostic imaging can identify MIBG-avid disease, while therapeutic use depends on tumor uptake and patient eligibility.

The relationship creates a potential platform effect: greater physician familiarity with MIBG biology can support diagnostic use. The therapeutic product also creates a clinical pathway in which diagnostic imaging and treatment selection are connected. The effect is limited because Azedra addresses a much smaller and more specialized patient population than general diagnostic imaging.

Azedra’s commercial performance does not provide a reliable proxy for AdreView revenue.

Which companies compete with iobenguane I-123?

Competition operates at three levels:

Direct radiopharmaceutical competition

This includes other suppliers of I-123 MIBG or equivalent diagnostic products. The direct supplier field is limited because radioactive drug manufacturing requires specialized facilities and regulatory controls.

Platform competition

PET radiopharmaceutical manufacturers compete by offering alternative imaging agents. Large nuclear medicine and radiopharmaceutical companies, hospital-based radiopharmacies, and regional isotope suppliers can compete indirectly through availability, reimbursement, and physician preference.

Clinical pathway competition

Imaging modalities such as PET/CT, MRI, CT, and conventional scintigraphy can replace or reduce I-123 use depending on the disease, clinical question, and local protocol.

The most important competitive variable is not unit price. It is whether the test changes clinical management and whether a hospital can obtain the dose reliably for a scheduled patient.

What is the Orange Book status of iobenguane I-123?

AdreView is associated with NDA 022164 in FDA drug databases. The Orange Book should be used to assess current patent listings, therapeutic-equivalence coding, and any approved generic or follow-on products.[3][4]

The commercial interpretation is straightforward:

FDA exclusivity from the original approval is no longer a meaningful barrier.
A biosimilar challenge is not applicable.
Any active patent protection must be evaluated at the listed-patent level.
A competing product could face substantial regulatory and manufacturing barriers even if patent blocking is limited.

What generic launch scenarios exist for iobenguane I-123?

Scenario 1: No meaningful generic entry

This is the most commercially plausible outcome if the market remains small and existing supply is adequate. The incumbent retains demand through manufacturing reliability and established hospital relationships.

Scenario 2: Limited regional competition

A second supplier enters selected U.S. regions or hospital networks. The effect is greater supply resilience and modest price pressure, but not a rapid erosion of the entire market.

Scenario 3: 505(b)(2) or equivalent follow-on product

A competitor relies partly on published information while developing a differentiated formulation, labeling process, or supply model. The product could compete through availability and service rather than deep price discounting.

Scenario 4: Technology substitution

PET adoption reduces I-123 volume without a direct generic launch. This is the most important long-term competitive risk because it attacks utilization rather than price.

What licensing deals and litigation affect the market?

No major publicly disclosed licensing transaction or high-profile patent settlement is central to the U.S. iobenguane I-123 market. The commercial model is more likely to involve manufacturing, distribution, isotope-supply, or hospital procurement arrangements than large platform licensing deals.

Likewise, no widely reported litigation has established a market-wide injunction, launch delay, or settlement framework comparable to those seen in high-revenue branded pharmaceuticals. The absence of visible litigation is consistent with the product’s small market, mature chemistry, and operationally concentrated supply chain.

What is the revenue exposure for manufacturers and investors?

Product-specific revenue exposure is difficult to quantify because companies generally report radiopharmaceutical revenue in aggregated business segments. For an owner or supplier, the economic profile has several characteristics:

low absolute revenue compared with therapeutic oncology products;
relatively high value per administered dose;
concentrated customer base;
sensitivity to manufacturing outages;
limited inventory flexibility;
potential pricing resilience when supply is constrained;
gradual volume erosion risk from PET substitution.

The asset is more valuable as part of a broader radiopharmaceutical portfolio than as a standalone growth product. Portfolio ownership can spread isotope procurement, manufacturing, regulatory, and distribution costs across multiple products.

How strong is the iobenguane I-123 patent estate?

The patent estate appears commercially moderate to weak relative to a recently approved specialty drug. Core exclusivity is old, product demand is narrow, and the likely remaining barriers are operational rather than composition-of-matter patents.

Patent-estate factor	Assessment
Composition-of-matter protection	Mature
Regulatory exclusivity	Expired
Formulation protection	Potentially narrow
Method-of-use protection	Limited incremental value
Manufacturing know-how	Meaningful
Supply-chain barriers	High
Generic litigation risk	Moderate but economically constrained
PET substitution risk	More material than patent erosion

Key Takeaways

Iobenguane I-123, marketed in the United States as AdreView, is a specialized diagnostic radiopharmaceutical approved in 2008.
Its market is small, concentrated, and operationally constrained by the 13.2-hour half-life of iodine-123.
Product-level revenue is not publicly reported, preventing a reliable standalone sales forecast.
FDA exclusivity has expired, and the commercial moat depends more on manufacturing, isotope access, quality systems, and distribution than on basic patent protection.
No prominent Paragraph IV litigation, major patent settlement, or biosimilar pathway defines the market.
PET-based imaging is the principal long-term competitive threat.
The most plausible generic scenario is limited regional or specialized competition rather than rapid commoditization.
Financial performance is likely to be stable or gradually pressured in mature markets, with upside tied to specialized oncology utilization and supply reliability.

FAQs About Iobenguane I-123 Market and Patent Risk

Is iobenguane I-123 the same as Azedra?

No. Iobenguane I-123 is used for diagnostic imaging. Azedra contains iobenguane I-131 and is used therapeutically for selected pheochromocytoma and paraganglioma patients.

Does iobenguane I-123 have biosimilar competition?

No. It is a radiopharmaceutical drug, not a biologic. Any follow-on product would generally be evaluated through a generic, 505(b)(2), or other applicable drug pathway rather than a biosimilar pathway.

Why is iobenguane I-123 difficult to distribute?

Iodine-123 decays rapidly, with a half-life of about 13.2 hours. Manufacturers must coordinate production, quality release, shipment, and administration within a narrow time window.

Can PET imaging replace iobenguane I-123?

In some clinical settings, yes. PET tracers can offer higher resolution or more favorable workflow. I-123 remains relevant for MIBG-avid tumors and established neuroblastoma and pheochromocytoma imaging protocols.

Is AdreView a high-value pharmaceutical asset?

It is more valuable as part of a diversified radiopharmaceutical portfolio than as a standalone growth asset. Its strengths are established clinical use and specialized manufacturing requirements; its weaknesses are limited volume, short shelf life, and PET substitution risk.

References

U.S. Food and Drug Administration. (2023). AdreView (iobenguane I 123 injection) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
U.S. Food and Drug Administration. (2018). Azedra (iobenguane I 131 injection) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: AdreView, NDA 022164. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files.

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	16
Patent Applications:	583
DailyMed Link:	IOBENGUANE I-123 at DailyMed

Sponsor	Phase
Jubilant DraxImage Inc.	Phase 2
National Cancer Institute (NCI)	Early Phase 1
Mayo Clinic	Early Phase 1

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bwxt Medcl	IOBENGUANE I-123	iobenguane sulfate i-123	SOLUTION;INTRAVENOUS	213637-001	Dec 9, 2024		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

AI Deep Research

Questions you can ask:

Summary for IOBENGUANE I-123

Recent Clinical Trials for IOBENGUANE I-123